Introduction
For nearly four decades, primary care physicians, gastroenterologists, surgeons and oncologists have been fighting a losing battle against a relentless opponentoesophageal adenocarcinoma. During this period, the cancer has undergone an impressive and continuous rise in incidence, from a true rarity in the early 1970s to now being the most common histological type of oesophageal cancer in many developed countries. [1] [2] [3] Data from the Surveillance Epidemiology and End Results (SEER) registries in the USA that were published in 2014 show a more than eightfold rise (from 0.3 to 2.7 per 100,000) in overall annual incidence between 1973 and 2011, and a 10-fold increase (from 0.6 to 6.0 per 100,000) among white men ( Figure 1 ). 4 Some of the highest incidence rates of oesophageal adenocarcinoma in the world have been observed in the UK (9.4 per 100,000 men over [2008] [2009] [2010] . 5 Although treatment effectiveness has improved modestly over the past few decades (for example, 5-year relative survival in patients with oesophageal cancer has increased from 7.0% for patients diagnosed 1980-1984 to 20 .0% for patients diagnosed in 2006) about half of patients still die within a year of diagnosis. 6 These trends have occurred despite a background of improving medications and therapies for the disorders that can lead to oesophageal adenocarcinoma, which might have been expected to reduce the risk of this cancer. For example, H 2 receptor antagonists were introduced in the late 1970s, followed by the even more potent PPIs a decade later. At appropriate doses, these drugs can substantially reduce gastric acid production and the symptoms of GERD, which is a major risk factor for oesophageal adenocarcinoma. 7 Fundoplication was first described in the 1950s and gained popularity in the 1970s as a surgical means of increasing the effectiveness of the lower oesophageal sphincter and reducing or eliminating GERD. Unfortunately, these approaches do not seem to substantially reduce the i ncidence of oesophageal adenocarcinoma. [8] [9] [10] [11] Increasingly, gastroenterologists are focusing on the identification and long-term surveillance of patients with Barrett oesophagus to facilitate identifying and treating preinvasive or early-stage oesophageal adenocarcinoma. Photodynamic therapy began to be used in the 1990s as an endoscopic method of eliminating metaplastic or dysplastic cells of the oesophagus, but has largely been dropped because of frequent adverse effects and lack of clear benefit. 12 Over the past 15 years endoscopic therapies such an endoscopic mucosal resection combined with ablation techniques such as radiofrequency ablation have advanced considerably; they have become a common treatment for patients with high-grade dysplasia (a biomarker of high risk of neoplastic progression to oesophageal adenocarcinoma) and have even been proposed for use in patients at low risk. 13, 14 These procedures are now recommended over oesophagectomy (which is associated with high morbidity and mortality) for patients deemed to be at high risk of developing invasive cancer or who are not good candidates for surgery. 12 However, the jury is still out regarding the effectiveness of surveillance coupled with endoscopic therapy, as little evidence is available regarding the ultimate goal of reducing mortality from oesophageal cancer.
Although there is some room for optimism due to the improved treatments available, if Figure 1 is taken to heart, one can only conclude that primary and secondary prevention efforts in response to this mounting problem, which was first identified in the late 1980s, 15 have had minimal impact, at least on a population basis. Where did we go wrong?
The road taken A key reason for the failure of the current paradigm is that we are not identifying the 'at risk' population very effectively. The current strategy can be construed as representing not a 'war' on oesophageal adenocarcinoma, but rather a war on Barrett oesophagus. However, for the majority of patients, Barrett oesophagus is a benign condition that usually remains undiagnosed. In fact, the metaplastic epithelium might actually protect against the inflammatory and erosive effects of bile and acid reflux. 16, 17 In addition,
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some cases of oesophageal adenocarcinoma might occur without associated Barrett metaplasia, or in an ultra-short columnar tongue that might not be visible on endoscopy. Far from a 'lightning strike' , this war seems more akin to Napoleon's long, cold and ultimately fruitless march on Moscow in 1812-1813. 18 It is well known how that ended for soldiers and citizens on both sides, with vastly overstretched resources contributing to the rapidly diminishing size (from ~500,000 to ~10,000) of Napoleon's army over time, space and temperature, as famously depicted by Charles Minard. 19 The current situation in the field of oesophageal adenocarcinoma can be described using a representation similar to Charles Minard's map (Figure 2 ) in terms of the overall burden of oesophageal adenocarcinoma, the subgroups considered for diagnostic and surveillance endoscopy tests and the rapidly diminishing number of oesophageal adenocarcinoma cases that can be found in these subgroups, despite large expenditure on such endoscopic procedures. 20 Figure 2 is divided into four parts that estimate incidence rates and numbers of cases arising in: the overall adult population (labelled '1'); and in subgroups defined by presence of recurrent GERD symptoms (labelled '2' and '3'); whether screening endoscopy was carried out (labelled '4' and '5'); and whether Barrett oesophagus was diagnosed (labelled '6' and '7'). Unless noted otherwise, the incidence rates and percentages used in generating the estimates in Figure 2 are based on published literature.
Overall population
In the USA, ~17,000 cases of oesophageal cancer are diagnosed per year, 21 of which almost 60% (10,000) are adenocarcinomas. 1 Over 99% of cases of oesophageal adenocarcinoma in the general US population occur in people ≥40 years old, giving an at-risk population of ~150 million and yielding a crude incidence rate of 6.7 per 100,000 in this age group ( Figure 2 , section 1).
21,22
Recurrent GERD Population-based studies indicate that about 40% of oesophageal adenocarcinoma cases (4,000 per year) occur in people without chronic symptoms of GERD (that is, heartburn and/or regurgitation once per week or more). 23, 24 They comprise ~80% of the US adult population (120 million people), and have a crude annual incidence rate of 3.3 per 100,000 (section 2 of Figure 2 , labelled 'without GERD'). [25] [26] [27] The remaining cases (6,000) therefore occur among the 20% of the adult population (30 million people) who report GERD symptoms at least once per week, [25] [26] [27] [28] yielding an annual incidence rate of 20 per 100,000 (section 3 of Figure 2 , labelled 'with GERD'). Comparing crude incidence rates in people with and without chronic GERD symptoms yields a relative risk of oesophageal adenocarcinoma of six, which is consistent with published studies. 27, 28 Screening endoscopy Among patients with recurrent symptoms of GERD, only a small proportion, estimated at 10% (3 million people) in the USA, 20 undergo endoscopy in a given year to identify those with Barrett oesophagus for enrolment in a surveillance programme, to follow up those known to have Barrett oesophagus and/or to screen for early oesophageal adeno carcinoma (or other treatable conditions such as ulcer) that has not yet given rise to alarm symptoms ( Figure 2 , sections 4 and 5). 29 Assuming that patients who undergo endoscopy do not represent a random selection of those with symptoms of GERD, but rather, those with slightly higher risk (we estimate 30% higher) than those who do not undergo endoscopy due to reasons such as symptom severity and clinical acumen, the annual incidence in this group would be 26 per 100,000. The remaining 27 million people with recurrent GERD symptoms who do not undergo endoscopic screening would therefore experience a slightly lower annual incidence of 19.3 per 100,000, yielding 5,220 cases in this group.
Barrett oesophagus
Endoscopic investigation of people with recurrent GERD symptoms generally reveals Barrett oesophagus to be present in at least 8% of initial endoscopies, with the exact figure depending on the population being considered. [30] [31] [32] [33] Assuming an 8% prevalence of Barrett oesophagus (240,000 people) and an annual rate of progression to oesophageal adenocarcinoma of ~0.3% (300 per 100,000), 34 then 720 cases (about 7%) will have been diagnosed as a consequence of current prevention activities (Figure 2,  section 7) . A few cases of oesophageal adenocarcinoma would still be observed among people for whom Barrett metaplasia is not found at endoscopy, perhaps due to Barrett metaplasia being missed, a rapidly developing cancer or an oesophageal adenocarcinoma not arising in Barrett epithelium. Given the above numbers (8% prevalence of Barrett oesophagus and a progression rate of 0.3% in people positive for Barrett oesophagus), it can be calculated that 60 oesophageal adenocarcinomas would arise in this group, reflecting an incidence rate of 2.2 per 100,000 per year. We are not aware of published incidence rates for comparison.
Challenges
Underdiagnosis and overdiagnosis are increas ingly being recognized as major challenges for many cancers in devising screening and surveillance programmes that are both economically sensible and effective in reducing mortality. 35 These challenges are particularly apparent in the current approach to control of oesophageal adenocarcinoma, as described in Figure 2 , which paradoxically yields both o verdiagnosis and underdiagnosis.
Underdiagnosis occurs because >90% of cases arise in patients not involved in endoscopic diagnosis and surveillance pro grammes. 36 Current US 'best practice' advice states that, in the absence of alarm symptoms, endoscopic investigation is indicated only in patients with recurrent GERD symptoms who do not respond to PPIs. 29 Thus, a large proportion of cases (~40%) are missed simply because the individuals do not report sufficient symptoms of GERD. 27, 28 Most of these 4,000 individuals will eventually be diagnosed only after they develop alarm symptoms, at which time the cancer is typically too far advanced for effective treatment. 37, 38 An estimated 52% of patients with oesophageal adenocarcinoma will have had recurrent GERD symptoms, but were never investigated (Figure 2) . Reasons for these patients not being investigated are not clear, but probably involve a combination of patient characteristics, physician characteristics and issues of access to health care. These patients are also usually diagnosed at a late stage, and consequently have a very poor prognosis. 37 Conversely, overdiagnosis occurs because most (95%) individuals who do undergo periodic surveillance do not develop the cancer in their lifetime, which contributes to overstretching of health-care resources. 17, 35 Within the current paradigm, simply performing upper endoscopies on an increased proportion of people with reflux symptoms would only worsen the overdiagnosis problem without materially improving population-level mortality from oesophageal adenocarcinoma. Importantly, it is still not clear whether individuals diagnosed through surveillance programmes in the community setting actually experience improved survival.
36,39-41
A different direction
If Napoleon had paused as he neared Moscow to fully contemplate the likely outcome of his campaign, taking into account how poorly it had progressed up to that point, he might have changed course and chosen a different path, saving hundreds of thousands of lives in the process. An opportunity of similar magnitude presents itself today, as modelling indicates that the incidence of oesophageal adenocarcinoma will continue to increase through to 2030, and that ~160,000 deaths attributable to this cancer will occur in the USA alone over the next two decades. 42 A lesson we can learn from Napoleon is the importance of recognizing when an approach is not working and when resources are stretched too thin, so that a different direction can be plotted and tried.
Analysis of the neglected and uninvestigated subpopulations depicted in Figure 2 might give us a new perspective regarding the individuals on whom we should focus our efforts in a renewed and more scientifically focused attempt to win this war. One promising approach to cancer prevention is to consider each risk factor, or predictor, in its most important and costeffective context, that is, 'precision cancer prevention' . Current approaches presume that gastro-oesophageal reflux is the single overriding risk factor for oesophageal adenocarcinoma. 27, 28 However, a number of other strong risk factors for oesophageal adenocarcinoma have been identified; [43] [44] [45] [46] [47] [48] [49] [50] hence, it is now possible to categorize individuals into more precise risk groups, each of which can be targeted for further investigation and/or interventions for prevention in a manner that is appropriate for their absolute risk (annual incidence) of oesophageal adenocarcinoma. In particular, we propose a prevention approach based on four levels of risk, ranging in annual cancer incidence from about 7 per 100,000 in the general population and the general practice settings, to 1,000-fold higher (7,000 per 100,000) among those in a tertiary care setting for management of those at highest risk ( Table 1 ). The incidences in the lowest two strata are based on SEER data; 4 whereas incidence in the highest tier (7% per year) represents an approximate minimum risk at which surgical or endoscopic interventions might be reasonably applied. [51] [52] [53] The incidences in the third and fourth strata are set to be 10-fold and 100-fold higher, respectively, than the general population to illustrate the separation in risk that might be achieved with current information together with resources that might be available in the near future. The subpopulations triaged to the high-risk strata would be correspondingly reduced by 10-fold (or more) per level, depending on the sensitivity of such classification schemes.
In the general population (stratum 1), the main modifiable risk factors include obesity, cigarette smoking and diets low in fruit and vegetables. 54, 55 Of note, although chronic GERD is a key risk factor for oesophageal adenocarcinoma, it is not easily addressed at the general population level. 28 Given the well-recognized importance of these three factors for multiple other cancers, as well as for cardiovascular disease and other health outcomes, the marginal importance of the fairly rare occurrence of oesophageal adenocarcinoma is quite small in driving public policy towards modifying these risk factors. Nevertheless, it is still important to recognize that improvements in healthy behaviours at the population level might actually have as large, or larger, an effect on incidence and mortality attributable to oesophageal adenocarcinoma than the other more-targeted interventions discussed later in this article, as well as on the treatment of those with the cancer. 56, 57 In the office of the primary care provider (stratum 2), the absolute risk of a particular patient >40 years old might be considered about the same as in the general population. However, in the primary care setting, the possibilities are much greater for educating both provider and patient as to modifiable risk factors, and for those sufficiently motivated, actually encouraging modest behavioural changes. 31, 58 In this setting, additional information resources are available, such as medical and family history, 59 physical examination, blood or urine measures (as effective biomarkers are identified) [60] [61] [62] [63] and knowledge of their independent associations with cancer risk; therefore, a risk assessment tool, or risk calculator, can be used to educate and motivate patients. Further more, these additional resources can be used to identify the patients who are at an increased level of risk who should be considered for additional investigation. 57, 64 Although no highly penetrant germline mutations for oesophageal adenocarcinoma have been identified, evidence suggests the disease has a considerable polygenic hereditary component, 65 and the list of common mutations that confer small differences in risk is growing. [66] [67] [68] [69] Eventually, germline mutations might contribute to the al gorithms for predicting risk.
This stratum is one context in which a substantial improvement in referral decisions can be made rather easily. Instead of relying primarily on the history of gastrooesophageal reflux symptoms, multiple easily assessed risk factors, such as those listed in the first two strata in Table 1 , can be integrated into a single risk calculation, and only the patients who are above a threshold (10-fold higher than the general population is used as the example in Table 1 ) can be triaged to the next assessment stage. 31 Traditionally, the next level of assessment has involved referral to a gastroenterologist for endoscopy to enable visualization of abnormalities, including columnar epithelium, and to collect biopsy samples for histological assessment. However, over the past several years, a number of less invasive approaches that do not use endoscopy have shown promise for bringing this important assessment into the primary care setting (stratum 3) at substantially reduced costs. For example, a tethered capsule has been created using volume laser endomicroscopy, which uses frequency domain optical co herence tomography that can rapidly scan the oesophageal lumen at a 30 μm lateral resolution to enable this device to be used for screening for Barrett oesophagus. 70 In addition, molecular screening of the oesophagus using noninvasive methods might soon be shown to be practical. 71 For example, Cambridge University have developed the Cytosponge™ (Medical Research Council, London, UK), which can be used in the office setting without sedation and then the retrieved oesophageal epithelial cells are assessed in a diagnostic assay for Barrett oesophagus that detects trefoil factor 3 (TFF3). 72 This technique has a sensitivity of 80-90% depending on the length of the Barrett segment with a specificity of ~92%. 73 The technique can also identify lesions affecting the TP53 gene, which is an indication of high-grade dysplasia, with a sensitivity of 86% and a specificity of 100%; further clinical trials are ongoing. 74 Such molecular tests might also detect early cancers that have not necessarily arisen in the context of Barrett oesophagus. 74, 75 These emerging tests are still experimental. However, a substantial improvement in clinical practice could be achieved if tissuebased biomarkers (such as cell surface or somatic genetic markers) from the capsule sponge or other noninvasive techniques, together with other risk factors, [76] [77] [78] can be demonstrated to differentiate the minority with substantially increased risk (again, 10-fold higher is used as the example in Table 1 ) who can be referred to secondary care, from the majority whose absolute risk remains low. 79 For those who remain in stratum 3, chemopreventative agents (such as aspirin and statins) might be considered, as well as stronger encouragement to modify lifestyle (for example, smoking cessation, improved diet, weight loss and increased physical activity). 48, 50, [80] [81] [82] [83] [84] [85] Patients calculated to be at high risk based on all of the previously collected information would then be considered to have entered stratum 4 under the care of a secondary care provider. This group would be much smaller in size than the group of patients with recurrent GERD symptoms in the general population (1.5 million versus 30 million), but have a much higher average risk. Here, an absolute risk of 700 per 100,000 (0.7% per year), for example, would probably prompt an endoscopy with multiple patterned biopsies as well as biopsies directed at visible abnormalities. Information based on endoscopy and biopsy samples, such as somatic genetic abnormalities 74, 78, 86 and histological findings, 87 would then determine whether the patient could be moved back to stratum 3, entered into surveillance (remaining in stratum 4) or be triaged to the highest risk stratum. 75 Patients entering stratum 5 (tertiary care provider) would have an average absolute risk of developing oesophageal adenocarcinoma of 7 per 100 (7%) per year, based on the example in Table 1 . If proven to reduce the risk of mortality from oesophageal adenocarcinoma, surgical or endoscopic interventions (such as ablation and endoscopic mucosal resection) could be offered to this group, who could then be returned to stratum 4 for continued surveillance.
Conclusions
Over the past several decades, efforts directed towards primary prevention and early diagnosis of oesophageal adenocarcinoma have had very little effect on curtailing its rapidly increasing morbidity and mortality at the population level. Fortunately, much has been learned from epidemiological and clinical studies during this period regarding aetiological and other predictive risk factors (such as lifestyle, demographics, anthropometry, genetic and tissue-based biomarkers). In addition, new techniques and devices are being developed that offer promising opportunities for integrating what is now known about the development of the cancer into a scientifically sound c linical practice protocol. Such a protocol would be designed to start with a wide population base, including many patients who are not covered by current practices, and would triage individuals into progressively higher risk strata, each with risk-appropriate prevention, screening and treatment options. Methods to assess risk would also be stratum-specific. At the lowest strata, there would be minimal intervention and simple, cost-effective tools; whereas in the higher risk groups, clinicians would make use of increasingly precise, but also increasingly invasive and expensive, tools. Hence, the careful selection of tests and prevention activities at different stages should be favourable economically, in contrast to the current scenario of enrolling more and more patients into endoscopic surveillance with little regard to their absolute risk, and therefore little population benefit. Some of the technologies mentioned are still in research and development, and are not yet available for widespread adoption. In addition, development and validation of risk prediction algorithms for the middle three strata are important aspects of this approach. Such efforts have already begun, although they have been based on limited data and settings; 31, 38 thus, a good deal of development and validation work in this area still needs to be done, but the potential reward is high.
